Urbonaviciene et al. [17], have shown that a 1 mg/l increase in adiponectin levels was associated with a 22% decrease of MACE incidence in symptomatic PAD patients, but this effect was limited only to male participants. This evidence concerns the gene ADIPOQ and peripheral arterial disease.